Evaluation of adherence patterns in schizophrenia using electronic monitoring (MEMS®): A six-month post-discharge prospective study

Misdrahi, David; Tessier, Arnaud; Husky, Mathilde; Lange, Anne-Catherine; Vrijens, Bernard; Llorca, Pierre-Michel; Baylé, Franck Jean

doi:10.1016/j.schres.2017.06.026

Article (Scientific journals)

Evaluation of adherence patterns in schizophrenia using electronic monitoring (MEMS®): A six-month post-discharge prospective study

Misdrahi, David; Tessier, Arnaud; Husky, Mathilde et al.

2018 • In Schizophrenia Research, 193, p. 114-118

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/226834

DOI
10.1016/j.schres.2017.06.026

PubMed
28663027

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

201803_SchizophreniaResearch_Vol193_pp114-118.pdf

Publisher postprint (418.92 kB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Medication adherence; Schizophrenia; MEMS

Abstract :

[en] Background: Medication Event Monitoring System (MEMS®) is considered the gold standard for the evaluation of medication adherence, yet few studies have applied this method, especially over long periods of time. Objective: To investigate medication adherence patterns in a sample of post-discharge patients with schizophrenia monitored with MEMS caps during a six-month period. Method: Adherence to antipsychotics was prospectively investigate d using MEMS among 68 patients with schizophrenia. Treatment initiation, implementation or whether or not the patient takes his dosing regimen as prescribed, persistence or the length of time between initiation and discontinuation, and treatment discontinuation were used to describe adherence. Persistence over time was described using Kaplan-Meier curves. Results: After discharge 16% of the patients never initiated treatment. On average 37.3% of patients adhered to treatment in the ﬁrst 6 months. However, a strong decrease in adherence was observed over time (p < 0.0001), primarily due by treatment non-persistence. Only half of the patients were persistent at 6 weeks, persistence further dropped to 19.0% after 6 months. Among persistent patients, implementation was consistent over time with 87.8% of patients taking their medication as prescribed on any given day. Conclusions: Dosing proﬁle analysis provides further evidence for the magnitude of non-adherence with antipsychotic prescriptions among post-discharge patients with schizophrenia. Using the high precision of MEMS®, dosing proﬁles may provide a better understanding of non-adherence patterns and help clinicians determine optimal individualized strategies.

Disciplines :

Psychiatry

Author, co-author :

Misdrahi, David; Université Bordeaux 1 > Centre Hospitalier Charles Perrens > Neuroimagerie et cognition humaine

Tessier, Arnaud; Université Bordeaux 1 > Centre Hospitalier Charles Perrens

Husky, Mathilde; Université Bordeaux 1 > Institut Universitaire de France > Laboratoire de Psychologie

Lange, Anne-Catherine ; WestRock > Healthcare

Vrijens, Bernard ; WestRock > HealthCare

Llorca, Pierre-Michel; Université d'Auvergne > Faculté de Médecine

Baylé, Franck Jean; Université Bordeaux 1 > Centre Hospitalier Charles Perrens

Language :

English

Title :

Evaluation of adherence patterns in schizophrenia using electronic monitoring (MEMS®): A six-month post-discharge prospective study

Publication date :

March 2018

Journal title :

Schizophrenia Research

ISSN :

0920-9964

Publisher :

Elsevier, Netherlands

Volume :

193

Pages :

114-118

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 01 August 2018

Statistics

Number of views

78 (14 by ULiège)

Number of downloads

3 (3 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Acosta, F.J., Bosch, E., Sarmiento, G., Juanes, N., Caballero-Hidalgo, A., Mayans, T., Evaluation of noncompliance in schizophrenia patients using electronic monitoring (MEMS) and its relationship to sociodemographic, clinical and psychopathological variables. Schizophr. Res. 107 (2009), 213–217.
Acosta, F.J., Ramallo-Fariña, Y., Bosch, E., Mayans, T., Rodríguez, C.J., Caravaca, A., Antipsychotic treatment dosing profile in patients with schizophrenia evaluated with electronic monitoring (MEMS®). Schizophr. Res. 146 (2013), 196–200.
Blaschke, T.F., Osterberg, L., Vrijens, B., Urquhart, J., Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu. Rev. Pharmacol. Toxicol. 52 (2012), 275–301.
Brain, C., Allerby, K., Sameby, B., Quinlan, P., Joas, E., Karilampi, U., Lindström, E., Eberhard, J., Burns, T., Waern, M., Drug attitude and other predictors of medication adherence in schizophrenia: 12 months of electronic monitoring (MEMS). Eur. Neuropsychopharmacol. 23 (2013), 1754–1762.
Byerly, M., Fisher, R., Whatley, K., Holland, R., Varghese, F., Carmody, T., Magouirk, B., Rush, A.J., A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Res. 133 (2005), 129–133.
Chesney, M.A., The elusive gold standard. Future perspectives for HIV adherence assessment and intervention. J. Acquir. Immune Defic. Syndr. 43:Suppl. 1 (2006), S149–S155.
Curson, D.A., Barnes, T.R., Bamber, R.W., Platt, S.D., Hirsch, S.R., Duffy, J.C., Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial. II. The incidence of compliance problems, side-effects, neurotic symptoms and depression. Br. J. Psychiatry 146 (1985), 469–474.
Diaz, E., Levine, H.B., Sullivan, M.C., Sernyak, M.J., Hawkins, K.A., Cramer, J.A., Woods, S.W., Use of the Medication Event Monitoring System to estimate medication compliance in patients with schizophrenia. J. Psychiatry Neurosci. 26 (2001), 325–329.
Diaz, E.F., Neuse, E., Sullivan, M.C., Pearsall, H.R., Woods, S.W., Adherence to conventional and atypical antipsychotics after hospital discharge. J. Clin. Psychiatry 65 (2004), 354–360.
Dolder, C.R., Lacro, J.P., Dunn, L.B., Jeste, D.V., Antipsychotic medication adherence: is there a difference between typical and atypical agents?. Am. J. Psychiatry 159 (2002), 103–108.
DSMIV, American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders. 4th ed, 1995, DSM IV, Washington DC.
George, C.F., Peveler, R.C., Heiliger, S., Thompson, C., Compliance with tricyclic antidepressants: the value of four different methods of assessment. Br. J. Clin. Pharmacol. 50 (2000), 166–171.
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W.F., Thibaut, F., Möller, H.-J., World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia, World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J. Biol. Psychiatry, 2012.
Kahn, R.S., Fleischhacker, W.W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I.P.M., Gheorghe, M.D., Rybakowski, J.K., Galderisi, S., Libiger, J., Hummer, M., Dollfus, S., López-Ibor, J.J., Hranov, L.G., Gaebel, W., Peuskens, J., Lindefors, N., Riecher-Rössler, A., Grobbee, D.E., EUFEST study group, Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371 (2008), 1085–1097.
Kay, S.R., Fiszbein, A., Opler, L.A., The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13 (1987), 261–276.
Kemmler, G., Hummer, M., Widschwendter, C., Fleischhacker, W.W., Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Arch. Gen. Psychiatry 62 (2005), 1305–1312.
Lacro, J.P., Dunn, L.B., Dolder, C.R., Leckband, S.G., Jeste, D.V., Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J. Clin. Psychiatry 63 (2002), 892–909.
Lieberman, J.A., Stroup, T.S., McEvoy, J.P., Swartz, M.S., Rosenheck, R.A., Perkins, D.O., Keefe, R.S.E., Davis, S.M., Davis, C.E., Lebowitz, B.D., Severe, J., Hsiao, J.K., Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators, Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353 (2005), 1209–1223.
Llorca, P.-M., Partial compliance in schizophrenia and the impact on patient outcomes. Psychiatry Res. 161 (2008), 235–247.
Misdrahi, D., Tessier, A., Swendsen, J., Berna, F., Brunel, L., Capdevielle, D., Chereau, I., Danion, J.-M., De Pradier, M., Dorey, J.-M., Dubertret, C., Dubreucq, J., Faget, C., Gabayet, F., Rey, R., Richieri, R., Passerieux, C., Schandrin, A., Schurhoff, F., Tronche, A.M., Urbach, M., Llorca, P.-M., Fond, G., for the FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) Group, Determination of adherence profiles in schizophrenia using self-reported adherence. J. Clin. Psychiatry, 2016, e1130–e1136.
Nakonezny, P.A., Byerly, M.J., Electronically monitored adherence in outpatients with schizophrenia or schizoaffective disorder: a comparison of first- vs. second-generation antipsychotics. Schizophr. Res. 82 (2006), 107–114.
Nakonezny, P.A., Byerly, M.J., Rush, A.J., Electronic monitoring of antipsychotic medication adherence in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of its reliability and predictive validity. Psychiatry Res. 157 (2008), 259–263.
Nose, M., Barbui, C., Tansella, M., How often do patients with psychosis fail to adhere to treatment programmes? A systematic review., 33, 2003, 1149–1160.
Osterberg, L., Blaschke, T., Adherence to medication. N. Engl. J. Med. 353 (2005), 487–497.
Remington, G., Kwon, J., Collins, A., Laporte, D., Mann, S., Christensen, B., The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia. Schizophr. Res. 90 (2007), 229–237.
Valenstein, M., Blow, F.C., Copeland, L.A., McCarthy, J.F., Zeber, J.E., Gillon, L., Bingham, C.R., Stavenger, T., Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr. Bull. 30 (2004), 255–264.
Velligan, D.I., Lam, Y.-W.F., Glahn, D.C., Barrett, J.A., Maples, N.J., Ereshefsky, L., Miller, A.L., Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr. Bull. 32 (2006), 724–742.
Velligan, D.I., Wang, M., Diamond, P., Glahn, D.C., Castillo, D., Bendle, S., Lam, Y.W., Ereshefsky, L., Miller, A.L., Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr. Serv. 58 (2007), 1187–1192.
Velligan, D.I., Weiden, P.J., Sajatovic, M., Scott, J., Carpenter, D., Ross, R., Docherty, J.P., The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J. Clin. Psychiatry 70:Suppl. 4 (2009), 1–46 (quiz 47–8).
Vrijens, B., De Geest, S., Hughes, D.A., Przemyslaw, K., Demonceau, J., Ruppar, T., Dobbels, F., Fargher, E., Morrison, V., Lewek, P., Matyjaszczyk, M., Mshelia, C., Clyne, W., Aronson, J.K., Urquhart, J., ABC Project Team, A new taxonomy for describing and defining adherence to medications. Br. J. Clin. Pharmacol. 73 (2012), 691–705.
Weiden, P., Glazer, W., Assessment and treatment selection for “revolving door” inpatients with schizophrenia. Psychiatr Q. 68 (1997), 377–392.
Yang, J., Ko, Y.-H., Paik, J.-W., Lee, M.-S., Han, C., Joe, S.-H., Jung, I.-K., Jung, H.-G., Kim, S.-H., Symptom severity and attitudes toward medication: impacts on adherence in outpatients with schizophrenia. Schizophr. Res. 134 (2012), 226–231.